These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 17482893)

  • 1. Live and let die: in vivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotection.
    Milsom MD; Williams DA
    DNA Repair (Amst); 2007 Aug; 6(8):1210-21. PubMed ID: 17482893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vector design for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.
    Schambach A; Baum C
    DNA Repair (Amst); 2007 Aug; 6(8):1187-96. PubMed ID: 17482894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. O6-methylguanine-DNA-methyltransferase (MGMT) gene therapy targeting haematopoietic stem cells: studies addressing safety issues.
    Sorg UR; Kleff V; Fanaei S; Schumann A; Moellmann M; Opalka B; Thomale J; Moritz T
    DNA Repair (Amst); 2007 Aug; 6(8):1197-209. PubMed ID: 17499560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells.
    Ragg S; Xu-Welliver M; Bailey J; D'Souza M; Cooper R; Chandra S; Seshadri R; Pegg AE; Williams DA
    Cancer Res; 2000 Sep; 60(18):5187-95. PubMed ID: 11016647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonal inventory screens uncover monoclonality following serial transplantation of MGMT P140K-transduced stem cells and dose-intense chemotherapy.
    Giordano FA; Sorg UR; Appelt JU; Lachmann N; Bleier S; Roeder I; Kleff V; Flasshove M; Zeller WJ; Allgayer H; von Kalle C; Fruehauf S; Moritz T; Laufs S
    Hum Gene Ther; 2011 Jun; 22(6):697-710. PubMed ID: 21319998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-expression of MGMT(P140K) and alpha-L-iduronidase in primary hepatocytes from mucopolysaccharidosis type I mice enables efficient selection with metabolic correction.
    Wang D; Worsham DN; Pan D
    J Gene Med; 2008 Mar; 10(3):249-59. PubMed ID: 18076130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Trial of MGMT(P140K) Gene Therapy in the Treatment of Pediatric Patients with Brain Tumors.
    Kramer B; Singh R; Wischusen J; Dent R; Rush A; Middlemiss S; Ching YW; Alexander IE; McCowage G
    Hum Gene Ther; 2018 Aug; 29(8):874-885. PubMed ID: 29385852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene.
    Zhao H; Pestina TI; Nasimuzzaman M; Mehta P; Hargrove PW; Persons DA
    Blood; 2009 Jun; 113(23):5747-56. PubMed ID: 19365082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stem cell selection in vivo using foamy vectors cures canine pyruvate kinase deficiency.
    Trobridge GD; Beard BC; Wu RA; Ironside C; Malik P; Kiem HP
    PLoS One; 2012; 7(9):e45173. PubMed ID: 23028826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterisation of a P140K mutant O6-methylguanine-DNA-methyltransferase (MGMT)-expressing transgenic mouse line with drug-selectable bone marrow.
    Kramer BA; Lemckert FA; Alexander IE; Gunning PW; McCowage GB
    J Gene Med; 2006 Sep; 8(9):1071-85. PubMed ID: 16927363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells.
    Milsom MD; Jerabek-Willemsen M; Harris CE; Schambach A; Broun E; Bailey J; Jansen M; Schleimer D; Nattamai K; Wilhelm J; Watson A; Geiger H; Margison GP; Moritz T; Baum C; Thomale J; Williams DA
    Cancer Res; 2008 Aug; 68(15):6171-80. PubMed ID: 18676840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging stem cell-derived persistent foci after in vivo selection of lentiviral MGMT-P140K transduced murine bone marrow cells.
    Lin Y; Cheung P; Roth JC; Wilson DL; Gerson SL
    Mol Ther; 2011 Jul; 19(7):1342-52. PubMed ID: 21304493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug selection of mutant methylguanine methyltransferase from different oncoretroviral backbones results in multilineage hematopoietic transgene expression in primary and secondary recipients.
    Davis BM; Reese JS; Lingas K; Gerson SL
    J Hematother Stem Cell Res; 2003 Aug; 12(4):375-87. PubMed ID: 12965075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic stem cell gene therapy of murine protoporphyria by methylguanine-DNA-methyltransferase-mediated in vivo drug selection.
    Richard E; Robert E; Cario-André M; Ged C; Géronimi F; Gerson SL; de Verneuil H; Moreau-Gaudry F
    Gene Ther; 2004 Nov; 11(22):1638-47. PubMed ID: 15284838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. F2A sequence linking MGMT(P140K) and MDR1 in a bicistronic lentiviral vector enables efficient chemoprotection of haematopoietic stem cells.
    Maier P; Heckmann D; Spier I; Laufs S; Zucknick M; Allgayer H; Fruehauf S; Zeller WJ; Wenz F
    Cancer Gene Ther; 2012 Nov; 19(11):802-10. PubMed ID: 23037811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MGMT enrichment and second gene co-expression in hematopoietic progenitor cells using separate or dual-gene lentiviral vectors.
    Roth JC; Alberti MO; Ismail M; Lingas KT; Reese JS; Gerson SL
    Virus Res; 2015 Jan; 196():170-80. PubMed ID: 25479595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O(6)-methylguanine-DNA methyltransferase(P140K).
    Maier P; Spier I; Laufs S; Veldwijk MR; Fruehauf S; Wenz F; Zeller WJ
    Gene Ther; 2010 Mar; 17(3):389-99. PubMed ID: 19865182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells.
    Jansen M; Sorg UR; Ragg S; Flasshove M; Seeber S; Williams DA; Moritz T
    Cancer Gene Ther; 2002 Sep; 9(9):737-46. PubMed ID: 12189523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Davis BM; Reese JS; Koç ON; Lee K; Schupp JE; Gerson SL
    Cancer Res; 1997 Nov; 57(22):5093-9. PubMed ID: 9371508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloablation is not required to select and maintain expression of the drug-resistance gene, mutant MGMT, in primary and secondary recipients.
    Bowman JE; Reese JS; Lingas KT; Gerson SL
    Mol Ther; 2003 Jul; 8(1):42-50. PubMed ID: 12842427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.